Market Cap : 441.57 B | Enterprise Value : 440.6 B | PE Ratio : 24.45 | PB Ratio : 5.79 |
---|
NYSE:JNJ has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NYSE:JNJ has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Johnson & Johnson's Enterprise Value is $440,601 Mil. Johnson & Johnson's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2022 was $19,950 Mil. Therefore, Johnson & Johnson's EV-to-FCF for today is 22.09.
The historical rank and industry rank for Johnson & Johnson's EV-to-FCF or its related term are showing as below:
During the past 13 years, the highest EV-to-FCF of Johnson & Johnson was 24.75. The lowest was 13.20. And the median was 19.72.
JNJ's EV-to-FCF is ranked better thanEV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2022-08-17), Johnson & Johnson's stock price is $168.33. Johnson & Johnson's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2022 was $6.870. Therefore, Johnson & Johnson's PE Ratio for today is 24.50.
For the Drug Manufacturers - General subindustry, Johnson & Johnson's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Johnson & Johnson's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Johnson & Johnson's EV-to-FCF falls into.
Johnson & Johnson's EV-to-FCF for today is calculated as:
EV-to-FCF | = | Enterprise Value (Today) | / | Free Cash Flow (TTM) |
= | 440600.675 | / | 19950 | |
= | 22.09 |
Johnson & Johnson's current Enterprise Value is $440,601 Mil.
Johnson & Johnson's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $19,950 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Johnson & Johnson's PE Ratio for today is calculated as:
PE Ratio | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 168.33 | / | 6.870 | |
= | 24.50 |
Johnson & Johnson's share price for today is $168.33.
Johnson & Johnson's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $6.870.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Thank you for viewing the detailed overview of Johnson & Johnson's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Adamczyk Darius | director | 855 S. MINT STREET CHARLOTTE NC 28202 |
Hait William | officer: See Remarks | ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933 |
Mammen Mathai | officer: EVP, Pharm, R&D | THERAVANCE,INC. 901 GATEWAY BLVD. SOUTH SAN FRANCISCO CA 94080 |
Broadhurst Vanessa | officer: EVP, Global Corp Aff. | ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933 |
Swanson James D. | officer: EVP, Chief Information Officer | ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933 |
West Nadja | director | 1915 REXFORD ROAD CHARLOTTE NC 28211 |
Decker Robert J | officer: Controller, CAO | ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933 |
Joly Hubert | director | C/O BEST BUY CO, INC. 7601 PENN AVENUE SOUTH RICHFIELD MN 55423 |
Weinberger Mark A | director | METLIFE, INC. 200 PARK AVENUE NEW YORK NY 10166 |
Hewson Marillyn A | director | C/O CARPENTER TECHNOLOGY CORPORATION PO BOX 14662 READING PA 19612-4662 |
Mongon Thibaut | officer: Exec VP, WW Chair, Consumer | JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933 |
Wengel Kathryn E | officer: EVP, Chief GSC Officer | JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933 |
Wolk Joseph J | officer: Exec VP, CFO | JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933 |
Mcevoy Ashley | officer: EVP, WW Chair, Medical Devices | JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933 |
Taubert Jennifer L | officer: EVP, WW Chair, Pharmaceuticals | JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA NEW BRUNSWICK NJ 08933 |
From GuruFocus
Other Sources
By Zacks 2022-03-30
By Zacks 2022-03-30
By tipranks.com 2022-03-16
By Zacks 2022-03-15
By Zacks 2022-03-21
By Zacks 2022-03-22
By Fool 2022-03-31
By Zacks 2022-03-30
By Zacks 2022-03-24
By Zacks 2022-03-22
By Zacks 2022-03-21
By Zacks 2022-03-28
By Zacks 2022-03-25
By Zacks 2022-03-18